Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
ISS02 - Industry Supported Symposium: ALK and ROS1 in NSCLC: Optimising the Continuum of Care - Pfizer Oncology
- Type: Industry Supported Symposium
- Track:
- Presentations: 8
- Moderators:B. Solomon
- Coordinates: 12/04/2016, 13:45 - 15:15, Lehar 3-4
-
+
ISS02.01 - Welcome & Introduction
13:45 - 13:50 | Author(s): B. Solomon
- Abstract
No abstract available for this presentation
-
+
ISS02.02 - The Importance of Molecular Testing in NSCLC
13:50 - 14:00 | Author(s): B. Solomon
- Abstract
No abstract available for this presentation
-
+
ISS02.03 - ALK+ NSCLC: How Can We Maximise Clinical Outcome Today?
14:00 - 14:20 | Author(s): N. Girard
- Abstract
No abstract available for this presentation
-
+
ISS02.04 - Clinical Consequences of Resistance to ALK Inhibitors
14:20 - 14:40 | Author(s): C. Lovly
- Abstract
No abstract available for this presentation
-
+
ISS02.05 - Panel Discussion
14:40 - 14:50 | Author(s): B. Solomon
- Abstract
No abstract available for this presentation
-
+
ISS02.06 - ROS1+ NSCLC: Clinical Data and Experience
14:50 - 15:05 | Author(s): B. Solomon
- Abstract
No abstract available for this presentation
-
+
ISS02.07 - Panel Discussion
15:05 - 15:10 | Author(s): B. Solomon
- Abstract
No abstract available for this presentation
-
+
ISS02.08 - Meeting Close
15:10 - 15:15 | Author(s): B. Solomon
- Abstract
No abstract available for this presentation
-
+
SC11 - ALK, ROS1 and Rare Mutations in NSCLC
- Type: Science Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 5
- Moderators:D. Kim
- Coordinates: 12/05/2016, 16:00 - 17:30, Lehar 1-2
-
+
SC11.01 - Optimal Application & Sequence of ALK Inhibition Therapy
16:00 - 16:20 | Author(s): B. Solomon
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA07 - ALK-ROS1 in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:N. Singh
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 1-2
-
+
MA07.11 - Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC)
12:12 - 12:18 | Author(s): E. Felip
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA08 - Treatment Monitoring in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:R. Perez-Soler
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 3-4
-
+
MA08.01 - A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
11:00 - 11:06 | Author(s): H. Wakelee
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA16 - Novel Strategies in Targeted Therapy
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:G. Purkalne
- Coordinates: 12/07/2016, 14:20 - 15:50, Strauss 2
-
+
MA16.09 - Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
15:14 - 15:20 | Author(s): A. Drilon
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
